Search results for "multiple sclerosis"

showing 10 items of 630 documents

Cognitive impairment in multiple sclerosis can be predicted by imaging early in the disease.

2008

Background: Cognitive impairment is common in multiple sclerosis (MS) and adds significantly to the burden of the disease. The ability to predict future cognitive impairment from imaging obtained at disease onset has not been investigated. Methods: 62 patients imaged within 3 months of a clinically isolated syndrome were assessed neuropsychologically 7 years later. Baseline and periodic MRI measures of lesions, atrophy and normal-appearing white and grey matter were regressed against neuropsychological scores to explore the best predictors of cognitive outcome. Results: 28 patients had developed clinically definite MS at follow-up and a further nine met revised McDonald criteria for MS. Def…

AdultMalePathologymedicine.medical_specialtyPediatricsMagnetic Resonance SpectroscopyAdolescentGrey matterNeuropsychological TestsCerebral VentriclesWhite matterCohort StudiesDisability EvaluationAtrophyMultiple Sclerosis Relapsing-RemittingPredictive Value of TestsmedicineHumansProspective StudiesNeurologic ExaminationAspartic AcidClinically isolated syndromeMultiple sclerosisCognitive disorderNeuropsychologyBrainMcDonald criteriaDipeptidesMiddle Agedmedicine.diseaseCognitive impairment: multiple sclerosisMagnetic Resonance ImagingPsychiatry and Mental healthmedicine.anatomical_structureSurgeryFemaleNeurology (clinical)AtrophyPsychologyCognition DisordersInositolFollow-Up StudiesJournal of neurology, neurosurgery, and psychiatry
researchProduct

Safety of potential breast milk exposure to IFN-β or glatiramer acetate

2019

ObjectiveTo determine whether potential breast milk exposure to interferon-beta (IFN-β) or glatiramer acetate (GA) is safe for the infant.MethodsWe identified 74 infants born to 69 women with MS who breastfed under IFN-β (n = 39), GA (n = 34), or both (n = 1). Women had been enrolled into the German Multiple Sclerosis and Pregnancy Registry during pregnancy. Data were obtained from standardized, telephone-administered questionnaires completed by the mother during pregnancy and at 1, 3, 6, and 12 months postpartum and the infant's take-home medical record.ResultsThe median duration of exposed breastfeeding was 8.5 months (wide interquartile range: 4.9–12.7 months). Physical growth curves dur…

AdultMalePediatricsmedicine.medical_specialtyMultiple Sclerosis41BreastfeedingBreast milkArticleChild DevelopmentPregnancyInterquartile rangemedicineHumansImmunologic FactorsRegistriesGlatiramer acetatePregnancyMilk Humanbusiness.industryPostpartum PeriodInfantGlatiramer AcetateInterferon-betamedicine.disease54Pregnancy ComplicationsBreast FeedingNeurologyFemaleMedian bodyNeurology (clinical)businessBreast feedingPostpartum periodmedicine.drugNeurology - Neuroimmunology Neuroinflammation
researchProduct

Oral health status of a population with multiple sclerosis.

2010

Objective: To determine the oral treatment needs of a sample of patients diagnosed with multiple sclerosis in the Community of Madrid (Spain). Patients and methods: A cross-sectional epidemiological study was carried out with a sample of 64 patients who were aged 25 to 77 years. They were distributed into homogeneous age groups: 54 years. In order to evaluate the oral health status and treatment requirements, the parameters and guidelines of the WHO were used. Results: The prevalence of caries was 100%, or very close in all three groups. As age increased, the morbidity rate decreased, but the mortality rate increased considerably. On analyzing gingival health, 65% of patients had calculus, …

AdultMalePediatricsmedicine.medical_specialtyMultiple SclerosisCross-sectional studymedicine.medical_treatmentHealth StatusPopulationDentistryOdontologíaOral HealthOral healthDentistry Oral Surgery & MedicineEpidemiologymedicineHumanseducationGeneral DentistryDenturesAgededucation.field_of_studybusiness.industryMultiple sclerosisMortality rateMiddle Aged:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseCross-Sectional StudiesOtorhinolaryngologyTooth DiseasesNeeds assessmentUNESCO::CIENCIAS MÉDICASSurgeryFemaleResearch-ArticleOdontostomatology for the Disabled or Special PatientsDenturesbusinessMouth DiseasesNeeds AssessmentMedicina oral, patologia oral y cirugia bucal
researchProduct

Interobserver Agreement in the Diagnosis of Multiple Sclerosis

1989

• Interobserver agreement in the clinical diagnosis of multiple sclerosis (MS) among six neurologists was evaluated. Three of them participated in a study of the clinical diagnosis of MS, the Italian Multicenter Study (IMS). The raters examined the clinical forms of MS of 50 patients randomly selected from among 430 patients recruited from the IMS. For each patient, neurologists were asked to make a diagnosis according to the McDonald-Halliday classification system of MS. The overall agreement on the diagnosis (MS present or absent) was fair, with no difference noted between the two groups of raters. Considering the six diagnostic levels instead, the reliability was higher for the neurologi…

AdultMalePediatricsmedicine.medical_specialtyMultiple Sclerosisbusiness.industryMultiple sclerosisMethodDiseasemedicine.diseaseSurgeryClinical trialArts and Humanities (miscellaneous)Multicenter studyClinical diagnosisMultiple SclerosiMethodsmedicineHumansFemaleNeurology (clinical)businessReliability (statistics)HumanArchives of Neurology
researchProduct

Endovascular treatment of CCSVI in patients with multiple sclerosis: clinical outcome of 462 cases

2013

Although it is still debated whether chronic cerebro-spinal venous insufficiency (CCSVI) plays a role in multiple sclerosis (MS) development, many patients underwent endovascular treatment (ET) of CCSVI. The objective of the study is to evaluate the outcome and safety of ET in Italian MS patients. Italian MS centers that are part of the Italian MS Study Group were all invited to participate to this retrospective study. A structured questionnaire was used to collect detailed clinical data before and after the ET. Data from 462 patients were collected in 33 centers. ET consisted of balloon dilatation (93 % of cases) or stent application. The mean follow-up duration after ET was 31 weeks. Mean…

AdultMalePediatricsmedicine.medical_specialtyMultiple Sclerosismedicine.medical_treatmentendovascular multiple sclerosis treatment venousDermatologyBalloon dilatationCohort StudiesSurveys and QuestionnairesMedicineHumansIn patientEndovascular treatmentAdverse effectBeneficial effectsbusiness.industryMultiple sclerosisEndovascular ProceduresStentBrainRetrospective cohort studyGeneral MedicineMiddle Agedmedicine.diseaseSurgeryPsychiatry and Mental healthTreatment OutcomeSpinal CordVenous InsufficiencySettore MED/26 - NeurologiaFemaleNeurology (clinical)businessMultiple sclerosis CCSVI Endovascular treatmentFollow-Up Studies
researchProduct

No Association Between Genetic Polymorphism at Codon 129 of the Prion Protein Gene and Primary Progressive Multiple Sclerosis

2011

AdultMalePrionsChromosomes Human Pair 20Primary Progressive Multiple SclerosisPolymorphism Single Nucleotide03 medical and health sciences0302 clinical medicineArts and Humanities (miscellaneous)HumansMedicineGenetic Predisposition to DiseasePrion proteinCodonGene030304 developmental biologyGenetics0303 health sciencesbusiness.industryMiddle AgedMultiple Sclerosis Chronic ProgressivePrnp geneFemaleNeurology (clinical)business030217 neurology & neurosurgeryArchives of Neurology
researchProduct

Translational value of choroid plexus imaging for tracking neuroinflammation in mice and humans.

2021

Neuroinflammation is a pathophysiological hallmark of multiple sclerosis and has a close mechanistic link to neurodegeneration. Although this link is potentially targetable, robust translatable models to reliably quantify and track neuroinflammation in both mice and humans are lacking. The choroid plexus (ChP) plays a pivotal role in regulating the trafficking of immune cells from the brain parenchyma into the cerebrospinal fluid (CSF) and has recently attracted attention as a key structure in the initiation of inflammatory brain responses. In a translational framework, we here address the integrity and multidimensional characteristics of the ChP under inflammatory conditions and question w…

AdultMaleProteomicsEncephalomyelitis Autoimmune ExperimentalMultiple SclerosisMiceNatalizumabCerebrospinal fluidImmune systemmedicineAnimalsHumansNeuroinflammationMultidisciplinarybusiness.industryMultiple sclerosisExperimental autoimmune encephalomyelitisNeurodegenerationBrainmedicine.diseaseMagnetic Resonance ImagingMice Inbred C57BLDisease Models AnimalBlood-Brain BarrierChoroid PlexusNeuroinflammatory DiseasesChoroid plexusFemalebusinessNeurosciencemedicine.drugProceedings of the National Academy of Sciences of the United States of America
researchProduct

Identification of Biomarkers in Cerebrospinal Fluid and Serum of Multiple Sclerosis Patients by Immunoproteomics Approach

2014

Multiple sclerosis (MS) is an autoimmune inflammatory demyelinating disease of the central nervous system. At present, the molecular mechanisms causing the initiation, development and progression of MS are poorly understood, and no reliable proteinaceous disease markers are available. In this study, we used an immunoproteomics approach to identify autoreactive antibodies in the cerebrospinal fluid of MS patients to use as candidate markers with potential diagnostic value. We identified an autoreactive anti-transferrin antibody that may have a potential link with the development and progression of MS. We found this antibody at high levels also in the serum of MS patients and created an immun…

AdultMaleProteomicsPathologymedicine.medical_specialtyImmunoproteinsimmunoproteomeCentral nervous systemDiseaseBiologymultiple sclerosisProteomicsArticlecerebrospinal fluidCatalysisImmunoproteomicslcsh:ChemistryInorganic ChemistryCerebrospinal fluidSettore BIO/13 - Biologia ApplicatamedicineHumansPhysical and Theoretical Chemistrylcsh:QH301-705.5Molecular BiologySpectroscopyMultiple sclerosisOrganic ChemistryTransferrinCase-control studyGeneral MedicineMiddle Agedmedicine.diseaseComputer Science Applicationsmedicine.anatomical_structurelcsh:Biology (General)lcsh:QD1-999Case-Control Studiesmultiple sclerosiserum biomarkerImmunologyanti-transferrin autoantibodiesbiology.proteinFemaleSettore MED/26 - Neurologiaanti-transferrin autoantibodieAntibodyBiomarkersInternational Journal of Molecular Sciences
researchProduct

Quality of life, depression and fatigue in mildly disabled patients with relapsing–remitting multiple sclerosis receiving subcutaneous interferon bet…

2011

Background: The precise relationships among quality of life, depression, fatigue and cognitive impairment in multiple sclerosis (MS) are complex and poorly understood. Objective: To assess the effects of subcutaneous interferon beta-1a on quality of life, depression and fatigue over 3 years in the COGIMUS study, and to examine the relationship between these outcomes and baseline cognitive status. Methods: COGIMUS was an observational 3-year trial assessing cognitive function in 459 patients with relapsing–remitting MS treated with subcutaneous interferon beta-1a. Results: In total, 331 patients completed the study (168 received interferon beta-1a, 44 µg subcutaneously three times weekly, a…

AdultMaleQuality of lifeLongitudinal studymedicine.medical_specialtyInjections Subcutaneousmultiple sclerosisRelapsing-Remitting Multiple SclerosisInterferon beta 1aYoung AdultMultiple Sclerosis Relapsing-RemittingAdjuvants ImmunologicQuality of lifeInternal medicinemedicineHumansYoung adultFatigueDepression (differential diagnoses)AgedDepressionbusiness.industryCognitive function; Depression; Fatigue; Interferon beta 1a; Longitudinal study; Quality of life; Relapsing-Remitting Multiple SclerosisMultiple sclerosisCognitive disorderInterferon beta-1aInterferon-betaMiddle Agedmedicine.diseaseClinical trialNeurologyPhysical therapymultiple sclerosis cognition interferon betaFemaleSettore MED/26 - NeurologiaCognitive functionNeurology (clinical)Longitudinal studyCognition DisordersbusinessInterferon beta-1amedicine.drugMultiple Sclerosis Journal
researchProduct

Association between multiple sclerosis, cancer risk, and immunosuppressant treatment: a cohort study

2017

Abstract Background The association between multiple sclerosis (MS) and cancer has long been investigated with conflicting results. Several reports suggest an increased cancer risk among MS patients treated with immunosuppressant (IS) drugs. Methods We performed a cohort study including MS patients recruited at the Neurological Department of the University of Palermo. Mean follow-up period was ten years for the whole cohort. We calculated cancer incidence among patients treated with IS. Incidence rates were compared in the cohort by calculating the relative risk according to length and dose of exposure to IS. Cancer incidence among MS patients was compared to cancer incidence in the general…

AdultMaleRiskmedicine.medical_specialtyMultiple SclerosisPopulationlcsh:RC346-429Cohort StudiesYoung Adult03 medical and health sciences0302 clinical medicineNeoplasmsInternal medicinemedicineHumansMultiple sclerosiCancer; Cohort study; Immunosuppressant; Multiple sclerosis; Treatment; Neurology (clinical)Prospective cohort studyeducationlcsh:Neurology. Diseases of the nervous systemCancerImmunosuppressanteducation.field_of_studybusiness.industryIncidenceMultiple sclerosisCancerRetrospective cohort studyGeneral MedicineMiddle Agedmedicine.diseaseSurgeryTreatment030220 oncology & carcinogenesisRelative riskCohortFemaleNeurology (clinical)Cohort studybusinessImmunosuppressive Agents030217 neurology & neurosurgeryResearch ArticleCohort studyBMC Neurology
researchProduct